1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Indoco Remedies Limited

Indoco Remedies Limited

INDOCO.NS
Indoco Remedies LimitedIN flagNational Stock Exchange of India
213.28
INR
+5.85
- -
19.66BMarket Cap
Indoco Remedies Limited
INDOCO.NS
(National Stock Exchange of India)

Recent

price

213.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
52.2
61.72
68.45
79.5
93
109.4
113.66
110.44
103.81
117.2
132.28
163.18
177.98
194.05
188.3
- -
206.21
Revenue per Share
5.55
5.03
4.64
6.29
8.99
8.89
8.36
4.47
-0.32
2.62
10.1
16.8
15.44
10.68
-8.46
- -
-10.95
Basic EPS, GAAP
-4.66
7.5
7.45
10.72
11.83
12.18
9.62
13.32
14.56
13.33
8.93
18.86
19.41
16.86
10.41
- -
- -
Free Cash Flow per Basic Share
1.09
1.24
1.27
1.29
1.64
3.58
0.26
1.92
1.22
0.36
0.3
1.5
2.25
2.25
1.59
- -
- -
Dividend per Share
30.3
14.17
16.55
19.58
25.55
29.19
35.7
38.26
37.27
38.76
48.48
63.19
76.53
84.97
79.23
- -
2.13
Book Value per Share
35.18
37.55
39.94
44.31
48.43
52.99
60.11
61.58
62.3
63.82
74.29
88.19
98.1
100.11
94.78
- -
84.18
Tangible Book Value per Share
92
92
92
92
92
92
92
92
91
92
92
92
92
92
87
- -
87
Basic Weighted Avg Shares
4,811
5,688
6,308
7,326
8,570
10,081
10,474
10,177
9,421
10,800
12,186
15,037
16,400
17,882
16,413
17,929
17,912
Sales/Revenue/Turnover
11.4
11.6
11.09
12.36
14.42
11.19
8
6.37
-0.99
4.48
13.06
14.65
12.05
7.99
-0.89
0.86
0.86
Operating Margin (%)
135
192
237
309
471
607
633
677
716
708
731
772
706
919
982
1,069
1,264
Depreciation Expense
511
463
427
580
828
819
771
412
-29
241
930
1,548
1,423
985
-737
-952
-952
Net Income, GAAP
9.66
9.6
11.92
19.75
24.4
17.17
15.26
14.95
- -
15.59
29.51
34.57
26.22
28.57
- -
- -
- -
Effective Tax Rate (%)
10.63
8.15
6.77
7.91
9.66
8.13
7.36
4.04
-0.31
2.23
7.64
10.29
8.67
5.51
-4.49
-5.31
-5.31
Profit Margin (%)
1,049
797
762
1,024
1,306
1,616
1,817
1,216
926
1,041
2,156
3,488
3,891
3,423
1,933
1,408
1,408
Working Capital
540
462
274
138
128
379
1,323
1,233
1,287
1,024
1,039
1,068
1,585
3,641
5,426
5,584
5,584
LT Debt
3,502
3,800
4,144
4,574
5,277
5,765
6,513
6,750
6,606
6,796
7,690
9,046
10,283
11,105
10,184
9,321
9,321
Total Equity
12.33
12.95
12.31
14.03
16.25
14.14
8.71
5.86
- -
4.32
11.36
13.23
11.78
6.63
- -
- -
- -
Return on Invested Capital (%)
14.08
20.34
17.43
26.35
30.53
25.04
17.66
8.92
- -
6.81
16.11
21.33
17.02
10.02
- -
- -
- -
Return on Capital (%)
17.34
22.62
30.17
34.83
39.83
32.49
25.78
12.08
-0.84
6.94
23.15
30.09
22.1
13.23
-10.01
-26.84
-26.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
5,047
- -
5,314
LT Borrowings
4,458
- -
5,160
LT Finance Leases
483
- -
423
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
- -
92
Market Capitalization
25,252
20,726
14,245

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,813
- -
11,934
Cash, Cash Equivalents & STI
232
- -
458
Accounts Receivable, Net
4,526
- -
4,892
Inventories
4,246
- -
4,052
Total Current Liabilities
9,850
- -
10,525
Payables & Accruals
- -
- -
- -
ST Debt
5,047
- -
5,314
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.3%
4.51%
-8.47%
Free Cash Flow
19.4%
41.8%
149.39%
Net Income, GAAP
-92.27%
-23.68%
29.03%
Sales/Revenue/Turnover
6.36%
8.5%
9.24%
Total Cash Common Dividend
74.19%
65.13%
-86.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,168
4,736
4,588
4,391
17,882
2025
4,243
4,307
4,024
3,839
16,413
2026
4,291
4,718
4,343
4,559
17,929

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.62
3.81
1.69
- -
10.68
2025
0.29
-1.09
-3.08
-4.48
-8.46
2026
-3.94
-1
-3.2
-2.57
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.25
2025
- -
- -
- -
- -
1.59
2026
- -
- -
- -
- -
- -
Similar Companies
RAMM Pharma Corp. (RAMM.CN)
Tibet Weixinkang Medicine Co., Ltd. (603676.SS)
Silo Wellness Inc. (SILO.CN)
Ventura Cannabis & Wellness Corporation (CVHIF)
Panaxia Labs Israel Ltd (PNAX.TA)
H. Lundbeck A/S (HLBBF)
Business
Indoco Remedies Limited is an integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations across therapeutic areas including anti-infectives, cardiovasculars, gastrointestinals, and pain management. The company offers a diverse portfolio of branded generics and prescription drugs in categories such as tablets, capsules, injectables, and ophthalmics; key brands include Citalop, Redipred, and Emcor; it also provides contract manufacturing services and exports formulations to regulated markets. Founded in 1976 and headquartered in Mumbai, India, Indoco operates manufacturing facilities in India with a presence in over 50 countries, primarily targeting emerging and developed markets in Latin America, Africa, and Southeast Asia. In recent developments, Indoco Remedies expanded its product pipeline with the launch of new formulations in dermatology and respiratory segments in 2024, alongside receiving US FDA approvals for additional generic injectables. The company strengthened its global footprint through a strategic partnership with a leading Latin American distributor for anti-infective products in early 2025 and completed a funding round to bolster R&D investments in complex generics. These initiatives reflect ongoing efforts to diversify beyond domestic sales, which account for a significant portion of revenue, while navigating regulatory enhancements at its Goa facility.